Paxalisib (GDC-0084)

Paxalisib (GDC-0084) is an inhibitor of MTOR and PI3K and related targets used in studies of PI3K-Akt-mTOR Signaling and Autophagy. It is especially relevant in autophagy, cancer, and cell signaling models, where defined compound exposure can be linked to growth-factor signaling, survival control, and nutrient-sensing outputs and autophagic flux, lysosomal turnover, and stress adaptation.

By inhibiting MTOR and PI3K and related targets, Paxalisib (GDC-0084) can be used to examine growth-factor signaling, survival control, and nutrient-sensing outputs and autophagic flux, lysosomal turnover, and stress adaptation. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In autophagy, cancer, and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving MTOR and PI3K and related targets
• Pathway perturbation studies connected to PI3K-Akt-mTOR Signaling and Autophagy
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Paxalisib (GDC-0084) is appropriate when a defined chemical perturbant is needed to connect MTOR and PI3K and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in autophagy, cancer, and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.